The YTHDF1 antibody is a crucial tool for studying the biological functions of YTHDF1 (YTH domain-containing family protein 1), a reader protein that recognizes N6-methyladenosine (m6A), the most abundant internal mRNA modification in eukaryotes. YTHDF1 selectively binds m6A-modified transcripts through its conserved YTH domain, facilitating mRNA translation by interacting with ribosomes and translation initiation factors. This protein plays a pivotal role in regulating gene expression, influencing processes like neurodevelopment, immune response, and tumor progression.
YTHDF1-specific antibodies are widely used in research to detect protein expression levels, subcellular localization (primarily cytoplasmic), and interactions via techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). Studies using these antibodies have revealed YTHDF1's involvement in cancers, where its upregulation often correlates with poor prognosis, metastasis, and therapy resistance. Additionally, YTHDF1 dysregulation is linked to neurological disorders, such as Alzheimer’s disease, and metabolic abnormalities.
The development and validation of high-affinity, specific YTHDF1 antibodies are essential for elucidating m6A-mediated regulatory mechanisms and exploring therapeutic targets. Researchers rely on these antibodies to dissect YTHDF1's context-dependent roles, advancing our understanding of epitranscriptomics in health and disease.